AstraZeneca plc (AZN) Given Underperform Rating at Credit Suisse Group AG
Credit Suisse Group AG reaffirmed their underperform rating on shares of AstraZeneca plc (LON:AZN) in a research report released on Friday. They currently have a GBX 4,000 ($52.21) price target on the biopharmaceutical company’s stock.
AZN has been the topic of a number of other reports. Societe Generale reaffirmed a buy rating and set a GBX 7,000 ($91.37) target price on shares of AstraZeneca plc in a research report on Wednesday, September 14th. Morgan Stanley raised their target price on shares of AstraZeneca plc from GBX 5,000 ($65.27) to GBX 5,800 ($75.71) and gave the stock an overweight rating in a research report on Friday, August 19th. Deutsche Bank AG reaffirmed a buy rating and set a GBX 5,800 ($75.71) target price on shares of AstraZeneca plc in a research report on Wednesday, September 28th. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc and gave the company a sell rating in a research note on Tuesday, September 6th. Finally, Jefferies Group reiterated a buy rating and set a GBX 5,800 ($75.71) price objective on shares of AstraZeneca plc in a research note on Wednesday, September 21st. Five investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. AstraZeneca plc has a consensus rating of Hold and a consensus target price of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) traded up 0.20% during trading on Friday, reaching GBX 5096.00. 982,622 shares of the company were exchanged. The company’s 50-day moving average is GBX 5,005.11 and its 200 day moving average is GBX 4,435.88. AstraZeneca plc has a 1-year low of GBX 3,680.00 and a 1-year high of GBX 5,505.00. The firm’s market capitalization is GBX 64.46 billion.
The business also recently declared a dividend, which was paid on Monday, September 12th. Stockholders of record on Thursday, August 11th were paid a GBX 68.70 ($0.90) dividend. This represents a dividend yield of 1.37%. The ex-dividend date was Thursday, August 11th.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.